Adoptive therapy with chimeric antigen receptor (CAR)-redirected T cells showed spectacular efficacy in the treatment of leukemia in recent early phase trials. Patient's T cells were ex vivo genetically engineered with a CAR, amplified and re-administered to the patient. While T cells mediating the primary response were predominantly of young effector and central memory phenotype, repetitive antigen engagement irreversible triggers T cell maturation leaving late memory cells with the KLRG1+ CD57+ CD7- CCR7- phenotype in the long-term. These cells preferentially accumulate in the periphery, are hypo-responsive upon TCR engagement and prone to activation-induced cell death. A recent report indicates that those T cells can be rescued by CAR provided CD28 and OX40 (CD134) stimulation. We discuss the strategy with respect to prolong the anti-tumor response and to improve the over-all efficacy of adoptive cell therapy. © 2013 Hombach and Abken.
CITATION STYLE
Hombach, A. A., & Abken, H. (2013). Young T cells age during a redirected anti-tumor attack: Chimeric antigen receptor-provided dual costimulation is half the battle. Frontiers in Immunology, 4(JUN). https://doi.org/10.3389/fimmu.2013.00135
Mendeley helps you to discover research relevant for your work.